Acrux Ltd   Report issue

For profit Phase 2
Founded: Melbourne Australia (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2006
NCT00372008
First Marketed Drug
2021
efinaconazole (jublia)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ACRUX DDS | ACRUX DDS PTY | Acrux DDS Pty Ltd | Acrux Pharma Pty Ltd

Active Ingredients

Marketed Drugs (4)

dapsone (aczone) (2023)

efinaconazole (jublia) (2021)

lidocaine (xylocaine) (2021)

prilocaine (citanest) (2021)

Drugs in Phase 2 Trials (1)

testosterone (delatestryl) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypogonadism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1